TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent ® (dupilumab) ...

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

The bear market induced by the Federal Reserve’s monetary tightening officially ended in 2023, but it seems no one remembered ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Sanofi and Regeneron’s Kevzara (sarilumab) has been approved by the US Food and Drug Administration (FDA) to treat active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing at ...

Regeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the FDA has approved a label expansion of the arthritis drug Kevzara (sarilumab). The drug is now approved in the United ...

Sanofi and Regeneron are committed to helping patients in the U.S. who are prescribed Kevzara gain access to the medicine and receive the support they may need. KevzaraConnect ®, a comprehensive ...